Good morning, and thank you for joining us at this year's Canaccord Genuity's MedTech, Diagnostics and Digital Health and Services Forum. My name is Caitlin Roberts, and I'm one of the medical device analysts here at Canaccord Genuity. I'm pleased to be joined this morning by Axogen, a regenerative medicine company and market leader in the field of peripheral nerve repair. With me today is Mike Dale, CEO, and Lindsey Hartley, CFO. Before we begin, I want to remind everyone of any relevant disclosures, which can be found on our conference and our firm website. We'll begin with a fireside chat, and if we have some time at the end for Q&A, we will do that as well. Let's get into the Q3. You guys had quite a lot of news intra-quarter and also on the latest earnings call.
Let's take a step back and just maybe provide us with a bit of an overview of the recent developments at Axogen.
Sure. The nice thing about Axogen I like to share with people is that there's not a lot new, insofar as what we're doing is we're just continuing the cadence of executing the strategic plan, and specifically, that's the various work streams. One of the most important work streams is expanding the sales footprint within each of the clinical application areas that we have prioritized so that we can have a touchpoint to all the service sites, and then in addition, have the capacity to meet and then develop the individual surgeons who might treat those patients. To put that in context, there's no part of the areas that we target today which are fully staffed such that they can serve all the providers.
That's the most important thing that's going on with Axogen is that we're building into each of these areas, and we still have several years ahead of us by each application area before we reach to full capacity support. The other element is that we've long focused on, for the last several years, coverage and reimbursement. We've made significant progress on that strategic initiative, frankly, even faster and more effectively than we'd even planned. While we still have gaps, for the most part, coverage and reimbursement is strategically no longer a decisive issue for us as an obstacle and is now a situation where it allows us, because we have good coverage and reimbursement in most of the areas that we work, the ability to focus on the clinical consultation as to, is this patient justified or not justified?
We no longer need to tend to the obstacles that come along with a lack of coverage and reimbursement. From an R&D standpoint, our pipeline, as we alluded, and not alluded, but explained very openly at our first Investor Day a couple years ago, we have various areas that we believe that are critical strategically to make progress in order to enable adoption in nerve repair. One of those is coaptation, which is, for those who are unfamiliar, very simply, how do you stick two nerves together? In our world, that's historically been done only by one method, because there's only one method to do it, and that was microsurgery, which are tiny hair-like sutures that require headlamps and skills in terms of how you actually sew to a nerve.
Making that simpler, making that faster, and mechanically more effective is a key opportunity to enable adoption of nerve repair, and we made significant progress on that with our recent acquisition of BioCircuit.
Great. You also raised guidance on the Q3 call. How are you feeling about the growth that you set out and the expectations there, and your ability to potentially outperform that in the short term and also the long term?
As confident as someone like Lindsey and I can be in our positions. The reason why I say that is there's no shortage of patients who could be better served by having their peripheral nerve function addressed. So our market opportunities are significant no matter where we play, and we're very under-penetrated relative to any one of these areas. So that very, very important consideration is not a factor to our growth. So what are the factors? Coverage and reimbursement was one. That's less of a factor than it's ever been. In fact, for the most part, it's not an issue in large specs. So that's not an issue. So what are the challenges? How do we basically work into those opportunities? This is footprint. It's commercial execution and maintenance of your sales process, and from a discipline standpoint.
We have well-characterized business models in terms of how to create and keep a customer. We believe these models are very elastic for many years to come. Our job, therefore, is expand this footprint and prosecute these business models. That is why we are very confident that we have the ability to continue to grow at a high rate, and to do so for years ahead.
Great. You touched on the reimbursement. Maybe let us just touch on that a little bit further. Reimbursements increasingly become an important part of the story, and you have seen positive policy updates from Cigna, Elevance, Aetna this year. Any other updates that you are expecting at this time, either from payers that have updated their policies and may need to broaden out their stances, or just from payers that you are still waiting to see any sort of positive coverage stance?
Sure. Effectively, we are 90% commercial lives are now covered for nerve work. That said, there are still small pockets of IDNs or individual geographic-specific payers that remain. Our plan is obviously to continue to get to a point where 100% coverage. We just had a payer two days ago, a small one, that removed the experimental designation and opened up peripheral nerve repair. So we will continue to knock those off, but the big ones are mostly behind us now.
How should investors think about the impact of those wins on procedure volumes in the near and the long term? I think you have noted that it takes time for these updates to flow through individual hospital systems. What have you seen so far with the recent updates?
Everything that we do becomes simpler and more predictable. When coverage reimbursement is a cloud that hangs over your work, as you might appreciate, the physician might be enthusiastically table-pounding desirous of adoption, but can't because of the things that you need to go through in order to overcome those kinds of obstacles. Once those obstacles are removed, the selling process simply becomes much simpler, it therefore becomes shorter, and the work that's involved is clinical consultation, not administrative management. Everything gets a little easier. One of the reasons why we can't really quantify, well, what has been the impact of this good news is the corollary is the reason why, is that when you have those obstacles, you hear about them every day. Someone's calling you and telling you, "I lost this doc, I lost this patient.
This hospital doesn't want to do it anymore because they're tired of fighting." Once that's out of the way, no one tells you, "Hey, I have good news today." Basically, you just don't have a conversation about coverage and reimbursement any longer, which means it's no longer a factor, and everything just moves more smoothly. We know what we want to do. From a consultation standpoint, we know the kind of positioning and the conversations we'd like to have, and now our work is more and more focused on that, which is really the important thing you want to get to. We just expect everything we've been doing, we're going to continue to do, it's just going to be more efficient and effective.
Turning to market development, you guys have been talking about prostate for some time now, but have been careful to discuss the potential here until some clinical signals were borne out, which they were in the Q3, and you held a call about it on Monday. Just maybe provide some color on the patients and the clinical sites there and what you've been learning.
Sure. The interesting thing about prostate is one of the first pilot studies that Axogen had done was many years ago. It was published in 2015, but was not acted upon, interestingly. Regardless of the reasons why, the data was very suggestive of what we see elsewhere is that, guess what? When you graft a nerve that's been removed, there's a high potential probability of benefit, and that was borne out in that original clinical experience. When we engage in our strategic plan process, the question for us is not whether or not there's a lot of opportunity to address the clinical problems. The challenge in our world is the heterogeneity of our various opportunities. A nerve is a nerve is a nerve, but a doctor is not a doctor is not a doctor. I.e., you might have an iatrogenic injury secondary to cancer intervention.
A breast oncologist, a plastic surgeon is a completely different universe than compared to that of a prostate surgeon or a trauma surgeon or an oral maxillofacial surgeon, or even a head and neck surgeon. These are very discrete, different silos of physician activity. You have the dilemma of, wow, there's this huge TAM, but then you got to step back and say, "Okay, but how do I go at it? Where do I go first?" To concentrate your efforts, we've had to select very specific clinical application areas and say, "Okay, this is where we're going to go. We can go a lot of places, but this is where we're going to go." That begs the question, well, why are you going to these areas?
One of the reasons we focused on the oncological applications are the fact that there's fewer service providers, fewer physicians involved in the process, so you have fewer people to interact with in order to make the clinical case. You also have the unique dynamic that these are planned procedures because of the cancer, which allows for the patient to be part of the equation in a very direct, meaningful way. Now, we always know that the patient, in theory, a part of healthcare today, but when you really dig into the details, their actual material opportunity to be part of that discussion is limited. Not in the case of things like breast cancer and the reconstruction or in the case of prostate, men considering the consequences of the intervention.
We've selected these because we think they're logistically simpler and a much greater opportunity based upon the emotive aspect to create and keep a customer. Finally, the clinical opportunity to add a meaningful benefit is very, very high. As we make success there, it makes nerve care more likely to be standard of care, and there is a natural ripple effect across all the various clinical applications. There was definitely very specific reasons for why we've targeted these, and hopefully that makes sense in terms of why.
Also on the call, you estimated about $750 million TAM with the indication.
Speak to the puts and takes on the math here. What does the ASP assume from a mix of bilateral versus unilateral versus maybe just nerve protection procedures? Does this $750 million TAM assume that you could penetrate all of the 110,000 annual robotic prostatectomy procedures in the U.S.?
Sure. We believe that breast and prostate are the most addressable of all the opportunities that we work in, for some of the reasons I have described. Logistics, and the fact that those populations that we are characterizing are already selected populations, insofar as they are not theoretical TAMs. These are very addressable TAMs. Why is that? Let us just run prostate. We know how many procedures occur each year. These are procedures where the prostate is removed, and even in the best of hands, these are traumatic procedures, even with robotics. Even when you preserve the nerve, physically, in terms of not physically excising it, we know there is damage that still occurs. All of those patients could benefit from protecting the nerves that are preserved afterwards. That is one part of the TAM.
All of those are eligible for protection, allowing those nerves to heal as well as they possibly can. Then with regards to actual nerve grafting, it is a very definitive situation where you have at least 40% of the patients, they have definitively had their nerves removed, either one or both. We know, based upon the clinical history, which is well-characterized over more than two decades, what happens when you remove those nerves. It is not a question if it is a bad outcome or a lesser outcome. It is only a question to what degree. In that sense, you have a situation where the value proposition, kind of like a Pascal's wager, you have absolutely nothing to lose because introducing a nerve graft is an immunologically benign structure. You are not adding risk to the patient. The risk is the fact that they have undergone cancer surgery.
The benefit is the probability of benefit based upon what we know about nerves' regenerative capacity. It is a very powerful value proposition. You know you have a situation that is not going to get better on its own, and by utilizing an advanced nerve graft in those situations, you can demonstrably, with high probability, mitigate the outcomes. I have so far have not met a single physician, nor have we encountered a patient or a provider who does not agree with that hypothesis.
And then you also touched on the Monday call about the question of reimbursement, as your survey work and Dr. Lee's opinion also pointed to likely willingness to pay out of pocket for the reconstruction, at least until more robust data collection could support coverage of the technology. How have systems, as part of your early clinical work, approached the use of technologies here? Also, are you starting to engage payers on the possibility of coverage for the indication?
To your last question, no, not yet. We're very hopeful, based upon all the market research we have done, that this situation will be navigable. The reasons why we're hopeful of that is for some of the reasons I've talked about, is that the import, the power of the value proposition is so high for the various stakeholders involved, that we think that that in itself will find a way forward. Very simplistically, without getting into detailed numbers, we know that part of the Medicare population will already be covered for nerve grafting. Amongst the commercial providers, we know that certain hospital systems are going to elect to cover this as part of their existing procedures because they believe it's, one, the right thing to do, and two, they see it as a hugely important competitive advantage relative to marketing for those patients.
We know from our research that the patients have basically said is that once a patient is aware that this is a probability, they will demand that they have a chance to have this. Because again, there's nothing to lose and potentially a lot to gain. So, those factors alone are quite unusual. Normally, I would say for a novel technology coming into this situation is you're going to have to really think differently about your market development and be very conservative. We think that because of what I've described, that we're going to have a better opportunity to get started while we wait for the next control data set to come out. But we'll find out, and the way we'll find out is we're going to test the hypothesis. We think 10 people is a good enough footprint in order to do that.
Based upon the experience in 2027 with those 10 territories, we will characterize the business model outcomes, and we will either modify or adapt, or we'll start scaling significantly.
To aid with that decision, any other key questions you are looking to answer here in the next year or so as you continue down the market and commercial development route and prepare for potential expanded commercialization?
For prostate?
No, really, we are confident in terms of what the value proposition is clinically. We are unconcerned. We have our own data set, and then we have historical data sets, and then we have more contemporary data sets already generated by physicians who have gone forward on their own. There is literally unanimity in terms of the outcomes. No one is telling us, "Oh, you know, this, I am not seeing good results, and maybe we should rethink." None of that. It is quite the opposite. As you might imagine, it is very encouraging. So we are very confident about that part of it. The only thing that we do not know is obviously, what is the bell curve in terms of customer creation, in terms of sell cycle, time, conversion ratios, and ability to adopt.
Obviously, we have a hypothesis, and we are going to go out and test it in 2027. Nothing really in addition to what I have shared.
Okay. Just turning to the BioCircuit NerveTape acquisition, could you provide the audience with an overview of why this acquisition, and also, why now?
Sure. To the last question, I have never been able to plan timing in my entire life. When something is right to do, you just do it, because if you say, "Well, I am going to wait for the better time," there is always something else that can come into life. Timing, we do not really honestly think about that much. As to the asset, why now? We have been watching this asset, as we disclosed, without disclosing the asset. We have been working on coaptation from the very first day that I arrived, as part of our planning process. We knew that strategically, this is the area where we wanted to invest, because this is the number one activity. It is basically the essence of our world, is putting two things together. If we could make advancements there to make it simpler, faster, and more effective, that is a beautiful thing.
The analogy I like to utilize with this asset is sometimes you can make things simpler, sometimes you can make things faster, sometimes you can make things more effective. Very rarely do you do all three. We think this trifecta is genuinely a new standard of care. We watched it for a very long time. The reason we waited to this point in time is that we wanted to see enough independent clinical data to confirm that the methodology, the form factor was benign. Okay? The whole point is to make sure that nerves have a chance to regenerate, and we needed to get comfortable that despite the bench work, that this was truly benign.
Once we got comfortable with that, then it was just a matter of building on the relationship that we already had with BioCircuit, and then coming to agreement.
Then just with the integration underway, and you've also given guidance for this year and next in terms of incremental NerveTape revenue, what needs to happen for you guys from a commercial standpoint to really execute on this guidance?
Lindsey?
Yeah. So we already have a lot of integration underway. We've already transitioned away from their independent broker model into our sales force. So it's in their hands, and they're already executing. We've transitioned the distribution of the product to be centralized in Texas already. We've integrated a lot of their systems, and we have purchase accounting underway. So we're very confident in how the integration is going so far.
Great. Then just how long is the tailwind to growth here? So how long do you think it'll take to get NerveTape into all of your accounts and then also start really expanding into the simple direct nerve repairs where you don't currently play already?
Sure. There's various buckets of priority. So the first priority is some of the things Lindsey just spoke to, is just the little logistics of integrating within the system and our distribution system. That's done. The second one is guidance with regards to our direct organization in terms of best use cases and where do we want them to prioritize. The first order step is to integrate within the existing strength areas that the technology had started within, in terms of applications. Then the second element is to work through the VAC process so that we go from 400 accounts to the more than 3,000 that we currently service, so that the technology is available for sale. So that's the priority. Then the fourth priority is that of moving forward into direct nerve repair. So it's obviously, as I just keep describing it's much simpler than sewing.
It's very fast, and it's mechanically more effective for the purpose. Uniquely, the reimbursement is more attractive for the facility and the physician to do these procedures with NerveTape than it would be to do so with sutures. There's really no barriers to it other than novelty. Novelty is a barrier. Everything still needs to be positioned and cultivated as a use case. That'll be an area that we go forward. Then finally, the fifth priority, and this is a longer-term play, is because this is so simple, and I encourage anyone who has not watched the movies, go online and watch the movies. It is literally that simple, is there's a potential strategically to bring other people into actual nerve reconnection or repair that are not nerve specialists, simply because you can do a quality repair without the previous microsurgical or nerve-specific focus.
When you think about some of the trauma situations, when you think about general orthopedic surgeons who are involved in some of these situations, they could actually do some of these procedures longer term. That's a longer-term element as part of the vision for this. In the near term, the first four priorities are really what will occupy our time.
Great. I think we're just out of time, so we'll leave it there, but thank you both.
Thank you.
Thank you.